March 13th 2025
Shionogi’s investigational antiviral is the first COVID-19 oral therapy that has shown this distinction.
March 13th 2025
Sarita Shah, MD, MPH, reveals a decline in timely ART initiation from 86.5% in 2019 to 83.9% in 2020, with viral suppression rates dropping from 91.1% to 84.7%, before showing signs of recovery by 2021.
March 7th 2025
Katherine L Kahn, MD, discusses the impact of restricted access to Paxlovid on hospitalization and mortality rates in a highly vaccinated population.
March 5th 2025
Pemivibart (Pemgarda) demonstrated activity against the LP81 variant.
March 3rd 2025
Approved vaccines for chikungunya, meningococcal disease, updates on HIV prevention, key regulatory decisions, and more.
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Tackling Inequities in IBD: Inclusive Solutions for Elevated Patient Care
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Addressing Racial Disparities in Multiple Myeloma: Forging a Path Towards Health Equity in Clinical Trials and Everyday Practice
View More
Mortality Rate: Severe COVID-19 vs Influenza
April 14th 2023People with COVID-19 who were hospitalized had a slightly higher rate of death than those with influenza. However, there were considerably more severe COVID-19 cases than the flu, leading to a much higher number of overall deaths associated with SARS-CoV-2.
Read More
COVID-19 in Pregnancy and Neurodevelopmental Disorders in Male Babies
April 5th 2023A retrospective study indicated higher rates of neurodevelopmental abnormalities in areas such as motor function and speech and language during the first year among babies born to women who had experienced a COVID-19 infection during pregnancy.
Read More
FDA Committee Endorses Full Approval of Paxlovid for COVID-19 Treatment
March 16th 2023The FDA's Antimicrobial Drugs Advisory Committee recommended approving Pfizer’s New Drug Application for Paxlovid to treat mild-to-moderate COVID-19 in adults at high risk of severe or fatal disease progression.
Read More
2 Commerce Drive
Cranbury, NJ 08512